ALLMedicine™ Prostate Cancer Center

Dec 3rd, 2021 - Black men are more likely than Non-Hispanic White (NHW) men to be diagnosed with high-risk prostate cancer (PCa). We examined the extent to which social factors were associated with differences in PCa risk profiles between Black men and NHW men (u...

Dec 3rd, 2021 - The quality of prostate cancer (PCa) content on Instagram is unknown. We examined 62 still-images and 64 video Instagram posts using #prostatecancer on 5/18/20. Results were assessed with validated tools. Most content focused on raising awareness ...

Dec 3rd, 2021 - While the existing knowledge base on the impact of prostate cancer (PC) and its treatment on sexuality and intimacy has been generated from Western populations, there is a lack of such evidence in the Asian context. This study aimed to explore men...

Dec 3rd, 2021 - Prostate cancer treatment planning is largely dependent upon examination of core-needle biopsies. The microscopic architecture of the prostate glands forms the basis for prognostic grading by pathologists. Interpretation of these convoluted 3D gla...

Dec 3rd, 2021 - Fibroblast activation protein (FAP) has been recently presented as new imaging target for malignant diseases and offers high contrast to surrounding normal tissue. FAP tracer uptake has been reported in various tumor entities. The aim of this stud...

Oct 5th, 2021 - Patients are the stewards of their own care and hence their voice is important when designing and implementing research. Patients should be involved not only as participants in research that impacts their care, as the recipients of that care and a...

Feb 6th, 2021 - The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. Recommendations for disease monitoring and treatment of r...

Jan 27th, 2021 - Update all preceding ASCO guidelines on initial hormonal management of noncastrate advanced, recurrent, or metastatic prostate cancer. The Expert Panel based recommendations on a systematic literature review. Recommendations were approved by the E...

Dec 15th, 2020 - ASTRO Editorial: The AUA-ASTRO-SUO Advanced Prostate Cancer Guidelines: A Continued but Changing Role for the Radiation Oncologist.|2020|Zietman AL, ,|radiotherapy,

Nov 12th, 2020 - To present a summary of the 2020 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-Internatio...

Dec 3rd, 2021 - This is a prospective (the participants are identified and then followed forward in time for the outcome of the study), multicenter (when more than one hospital or medical school team work on a medical research study), post-marketing surveillance ...

Dec 3rd, 2021 - This is a multicenter, open-label (participants will know the identity of study drug received) study in participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC). The study is a single sequence design (ie, all participants will tak...

Dec 3rd, 2021 - This study is a multicenter, randomized, double-blind, placebo controlled, dose finding study of VERU-944 to treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT. The study will have four arms with 30 subjects per arm...

Dec 3rd, 2021 - The purpose of this study is to see what effects, good and/or bad, proton based radiation combined with low dose chemotherapy and hormonal therapy, has on patients and their cancer.

Dec 3rd, 2021 - BACKGROUND: T-cell receptor alternate reading frame protein (TARP) is expressed by both normal and malignant prostate cancer tissue and is found in about 95% of prostate cancer specimens. TARP is immunogenic and hence is a target antigen for vacci...

Nov 22nd, 2021 - Antibody-drug conjugates (ADCs) targeting TROP2, HER2, and, most recently, B7H3 have taken the field of non–small cell lung cancer (NSCLC) by storm, said Melissa Johnson, MD. She added that the TROP2-directed ADC, datopotamab deruxtecan, has the p...

Nov 15th, 2021 - Key clinical point: Radical prostatectomy vs external beam radiotherapy (EBRT) is associated with significant improvement in cancer-specific mortality in patients with National Comprehensive Cancer Network (NCCN) high-risk and Johns Hopkins Univer.

Nov 15th, 2021 - Key clinical point: Prostrate-specific antigen (PSA) testing increased after the 2017 United States Preventive Services Task Force (USPSTF) draft statement for prostate cancer screening. Major finding: A relative increase of 12.

Nov 15th, 2021 - Key clinical point: Salvage low-dose-rate (LDR) prostate brachytherapy shows good survival in patients with low-/intermediate-risk prostate cancer who had local failure after external beam radiotherapy (EBRT). Major finding: The median follow-up w.

Nov 15th, 2021 - Institutional Perspectives in Cancer- Precision Medicine: Chaired by Jyoti Patel, MD The live filming of this virtual event in our IPC series is now on-demand. OncLive is proud to present the State of the Science Summits and a new virtual even...